|
|
|
|
|
Sponsored by: |
Point Therapeutics |
Information provided by: | Point Therapeutics |
ClinicalTrials.gov Identifier: | NCT00083239 |
The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.
Condition | Intervention | Phase |
Melanoma Skin Cancer |
Drug: talabostat (PT-100) tablets |
Phase II |
MedlinePlus related topics: | Cancer Melanoma Skin Cancer |
ChemIDplus related topics: | Talabostat mesylate Talabostat |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Georgia | |||||
Emory University/Winship Cancer Institute | |||||
Atlanta, Georgia, United States, 30322-1013 | |||||
United States, Illinois | |||||
University of Chicago | |||||
Chicago, Illinois, United States, 60637 | |||||
United States, Michigan | |||||
University of Michigan | |||||
Ann Arbor, Michigan, United States, 48109-0473 | |||||
United States, New Hampshire | |||||
Dartmouth-Hitchcock Medical Center | |||||
Lebanon, New Hampshire, United States, 03756-0001 | |||||
United States, Pennsylvania | |||||
University of Pittsburgh | |||||
Pittsburgh, Pennsylvania, United States, 15213-2582 | |||||
United States, Texas | |||||
Mary Crowley Medical Research Center | |||||
Dallas, Texas, United States, 75246 |
Point Therapeutics |
Study ID Numbers: | PTH-301 |
First Received: | May 14, 2004 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00083239 |
Health Authority: | United States: Food and Drug Administration |
|
|
|